|
FY2024
12 months to Dec 31, 2025
|
FY2023
12 months to Dec 31, 2024
|
FY2022
12 months to Dec 31, 2023
|
FY2021
12 months to Dec 31, 2022
|
FY2020
3 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation Expense | |||||
| Amortization of Intangible Assets | |||||
| Depreciation and amortization | |||||
| Equity-based compensation | |||||
| Goodwill impairment | |||||
| Provision for bad debts | |||||
| Paid in-kind interest expense | |||||
| Amortization of original issue discount and debt issuance costs | |||||
| Accretion of contingent consideration | |||||
| Gain on write off of contingent consideration | |||||
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | |||||
| Mark-to-market adjustment of stock warrants | |||||
| Premium deficiency reserve | |||||
| Impairment of assets held for sale | |||||
| Changes in operating assets and liabilities: | |||||
| Health plan receivable | |||||
| Clinic fees, insurance, and other receivable | |||||
| Prepaid expenses and other current assets | |||||
| Other long-term assets | |||||
| Accounts payable, accrued expenses, and other current liabilities | |||||
| Accrued payroll | |||||
| Health plan settlements payable | |||||
| Claims payable | |||||
| Accrued interest | |||||
| Operating lease liability | |||||
| Other long-term liabilities | |||||
| Deferred income taxes | |||||
| Net cash used in operating activities | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||
| Acquisitions, net of cash acquired | |||||
| Purchases of property and equipment | |||||
| Proceeds from asset sale | |||||
| Net cash provided by investing activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
| Proceeds from long-term debt, net of original issue discount | |||||
| Payment of debt issuance costs | |||||
| Proceeds from liability-classified warrants and private placement offering, net of offering costs paid | |||||
| Proceeds from at-the-market sales, net of offering costs paid | |||||
| Deferred offering costs paid | |||||
| Payment of tax withholdings upon settlement of restricted stock unit awards | |||||
| Repayment of short-term and long-term debt | |||||
| Proceeds from short-term debt | |||||
| Net cash provided by financing activities | |||||
| Net change in cash and restricted cash | |||||
| Cash and restricted cash, beginning of year | |||||
| Cash and restricted cash, end of year | |||||
| Supplemental disclosures of cash flow information: | |||||
| Interest Paid, Excluding Capitalized Interest, Operating Activity | |||||
| Income Taxes Paid | |||||
| Supplemental disclosures of non-cash investing and financing information: | |||||
| Operating lease liabilities arising from obtaining new right-of-use assets | |||||
| Operating Lease Right Of Use Assets Reduced Due To Lease Modification And Termination | |||||
| Increase in accrued expenses related to debt issuance costs and original issue discount | |||||
| Increase in accounts payable related to private placement offering costs | |||||
| Increase in accounts payable related to at-the-market offering costs | |||||
| Increase in accrued expenses related to at-the-market offering costs | |||||
| Increase in other receivable related to at-the-market sales proceeds | |||||
| Restricted stock unit awards issued in satisfaction of executive transaction bonuses | |||||
| Remeasurement adjustment to redeemable noncontrolling interest resulting from ownership changes | |||||
| Fair value adjustment to redeemable noncontrolling interest | |||||
| Warrants issued in connection with new debt | |||||
| Reconciliation of cash and restricted cash: | |||||
| Cash | |||||
| Restricted cash | |||||
Loading...